Revenue - Additional Information (Detail) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Mar. 18, 2025
Disaggregation Of Revenue [Line Items]
Revenue	$ 24,453,000		$ 11,684,000
One-time payment						$ 17,250,000
ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Product rights agreement, closing date	May 17, 2023
Receipt of upfront license fee	$ 75,000,000
RPA [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment	16,500,000
Revenue	12,700,000		300,000
Deferred revenue, current		$ 1,800,000			$ 1,800,000
Deferred revenue, non-current		10,900,000			10,900,000
Percentage of perpetual royalty obligation						3.125%
YUTIQ [Member]
Disaggregation Of Revenue [Line Items]
Revenue	600,000		700,000
Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue	715,000		658,000
Product [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue	0		0
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue	600,000		700,000
License and Collaboration Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue	11,049,000		10,563,000
License and Collaboration Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Revenue	200,000		100,000
Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Revenue	12,689,000		463,000
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue	0		200,000
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment	75,000,000
Guaranteed payments		1,875,000			7,500,000
Deferred revenue, current	5,100,000	15,900,000			15,900,000
Deferred revenue, non-current	$ 0	$ 0			$ 0
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period	2028
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Maximum [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Royalty payments				$ 70,000,000
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Minimum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period	2025
Product Rights Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 10,800,000		$ 10,400,000
Supply Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Initial term of the supply agreement	2 years
Initial Term of Estimated Supply Units	2 years